EUVIMEDEUVIMED entdecken
Crossref

Construction of a Hybrid Vaccine Based on Der f 35-Derived Peptides with Reduced Allergenicity

Haoyang Hu, Qiao-Zhi Qin, Wei Zheng, Zhi-Qiang Xu, Xiang Chen

International Archives of Allergy and Immunology · 2024

DOI: 10.1159/000541815 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2024. Verfasst von Haoyang Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Nantong University, Nantong, China. Hauptthemen laut MEDLINE: Antigens, Dermatophagoides, Allergens, Arthropod Proteins, Hypersensitivity. Die Arbeit nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

House dust mite is the primary trigger of allergic respiratory diseases worldwide, and allergen-specific immunotherapy (AIT) is the only disease-modifying treatment in the clinic. The use of allergen molecules instead of extracts is a promising strategy in AIT. In this study, we constructed a peptide hybrid vaccine against the major mite allergen Der f 35 and verified its hypoallergenicity, making it to be a promising candidate for AIT of mite allergy.

Methods

The gene encoding Der f 35 was retrieved and synthesized. The hypoallergenic peptide fragments derived from the B-cell epitopes were synthesized based on the predicted profiles of B-cell or T helper-cell epitopes in Der f 35, they were verified by immunoglobulin E (IgE)-reaction test and fused to non-allergenic protein carrier to form the hybrid vaccine. Both the wild-type Der f 35 and the designed vaccine were expressed in Escherichia coli and purified by chromatography; their IgE-binding activity was compared by indirect enzyme-linked immunosorbent assay (ELISA), Western blot, inhibition ELISA, and basophil activation test (BAT). The blocking immunoglobulin G (IgG) against the designed vaccine was raised in rabbits and its ability to inhibit IgE binding of Der f 35 was evaluated by ELISA. The vaccine’s effects on peripheral blood mononuclear cells (PBMCs) were investigated.

Results

A total of 29 out of 60 (48.33%) IgE-positive sera against Der f 35 were screened. Five peptide fragments (residue 39–42, 60–67, 73–107, 111–118, 126–143) from Der f 35 were selected as candidates, in which four peptides exhibited almost no IgE reactivity and the fragment 73–107 had weak reactions. Only 5.98–24.02% inhibition rates could be achieved by the peptides when compared with Der f 35 (97.32%). The designed vaccine migrated at approximately 30 kDa by SDS-PAGE. The IgE-ELISA revealed a significant reduction in IgE-binding activity to the vaccine when compared to wild-type Der f 35 (p < 0.0001); the decreased allergenicity was further confirmed by IgE-Western blot, inhibition ELISA, and BAT, respectively. The IgE-reactivity of Der f 35 could be blocked by the vaccine-induced IgG (p < 0.01). The levels of IL-5 and IL-13 from PBMCs were significantly decreased after stimulation by the vaccine than that by Der f 35 (p < 0.05).

Conclusion

The designed B-cell epitope vaccine of Der f 35 showed greatly diminished allergenicity and Th2 activity. It could be an effective and safe candidate to prevent allergic adverse reactions during the immunotherapy of mite allergy and merits the further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, DermatophagoidesAllergensArthropod ProteinsHypersensitivityVaccines, SubunitPeptidesAnimalsImmunoglobulin EHumansEpitopes, B-LymphocyteRabbitsImmunoglobulin GDesensitization, ImmunologicPyroglyphidaeEpitopes, T-Lymphocyte

Stichwörter der Autor:innen

AllergenB-cell epitopeHouse dust miteHypoallergenicityImmunotherapy

Substanzen

Antigens, DermatophagoidesImmunoglobulin EAllergensArthropod ProteinsEpitopes, B-LymphocyteImmunoglobulin GVaccines, SubunitPeptidesEpitopes, T-Lymphocyte

Autor:innen und Institutionen

  • School of Medicine, Nantong University, Nantong, China.
  • Pediatric Department, Northern Jiangsu People's Hospital, Yangzhou, China.
  • Department of Pharmacy, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Pharmacy, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Clinical Laboratory, The Second Affiliated Hospital of Nantong University, Nantong, China.

Zitieren

APA

Hu, H., Qin, Q. Z., Zheng, W., Xu, Z. Q., & Chen, X. (2024). Construction of a Hybrid Vaccine Based on Der f 35-Derived Peptides with Reduced Allergenicity. International Archives of Allergy and Immunology. https://doi.org/10.1159/000541815

Vancouver

Hu H, Qin QZ, Zheng W, Xu ZQ, Chen X. Construction of a Hybrid Vaccine Based on Der f 35-Derived Peptides with Reduced Allergenicity. International Archives of Allergy and Immunology. 2024. doi:10.1159/000541815

BibTeX
@article{Hu2024,
  author = {Hu, Haoyang and Qin, Qiao-Zhi and Zheng, Wei and Xu, Zhi-Qiang and Chen, Xiang},
  title = {Construction of a Hybrid Vaccine Based on Der f 35-Derived Peptides with Reduced Allergenicity},
  journal = {International Archives of Allergy and Immunology},
  year = {2024},
  doi = {10.1159/000541815}
}
Kostenlos starten →